Skip to main content

Table 2 Cox proportional-hazards model of risk factors for mortality or recurrence

From: Factors associated with recurrence and mortality in central line-associated bloodstream infections: a retrospective cohort study

Variables

Degrees of freedom

Hazard ratioa

95% confidence interval

P value

Age (per year)

1

1.021

1.004–1.037

0.01

Male

1

0.89

0.57–1.41

0.63

SOFA score (per point)

1

1.16

1.09–1.22

< 0.001

Immunosuppression presentb

1

1.58

0.91–2.73

0.10

All central lines removedc

1

0.71

0.43–1.17

0.18

High-risk organism presentd

1

1.33

0.81–2.17

0.26

Antimicrobial treatment duratione (14 versus 7 days)

2

0.35

0.26–0.48

< 0.001

  1. Age, SOFA score, and antimicrobial treatment duration were entered into the model as continuous variables; the remaining variables were entered as categorical variables
  2. Non-linearity was allowed for antimicrobial treatment duration by means of restricted cubic splines with three knots
  3. Linearity was assumed for other continuous variables
  4. The outcome was time to mortality or recurrence, censored at 60 days after the completion of antimicrobial therapy
  5. SOFA Sequential Organ Failure Assessment, CLABSI central line-associated bloodstream infection
  6. aThe hazard ratio for continuous variables compares each additional unit (e.g., the hazard ratio for age compares each additional year) except for antimicrobial treatment duration, for which it compares 14 days of antimicrobial treatment to 7 days
  7. bDefined as absolute neutrophil count less than 500 cells/mm3, human immunodeficiency virus with a CD4 count less than 200 cells/mm3, or prior organ transplant on active immunosuppression
  8. cDefined as all central lines removed within 4 days after CLABSI diagnosis
  9. dPrespecified as Staphylococcus aureus, Pseudomonas species, and Candida species
  10. eDefined as the continuous receipt of at least one antimicrobial to which the causative organism was sensitive, as determined by culture sensitivities; patients could miss no more than 1 consecutive day of antimicrobial therapy before treatment was considered complete unless they had therapeutic levels of an effective antimicrobial, as determined by monitoring of drug levels
Back to article page

Critical Care

ISSN: 1364-8535